1. Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review

   • Molly Lin
   • Sujin Park
   • Luke Y.C. Chen

   Review Article 12 May 2017 Pages: 1241 - 1251

   

2. Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?

   • Giovanni Di Minno
   • David Navarro
   • Andreas Tiede

   Review Article Open access 18 June 2017 Pages: 1253 - 1270

   

3. Vitamin D and plasma cell dyscrasias: reviewing the significance

   • Nicholas Burwick

   Review Article 13 May 2017 Pages: 1271 - 1277

   

4. Central nervous system involvement in adults with haemophagocytic lymphohistiocytosis: a single-center study

   • Guilan Cai
   • Yini Wang
   • Zhao Wang

   Original Article 07 June 2017 Pages: 1279 - 1285

   

5. Influence of TNF and IL6 gene polymorphisms on the severity of cytopenias in Argentine patients with myelodysplastic syndromes

   • Yesica Bestach
   • Virginia Palau Nagore
   • Carolina Belli

   Original Article 10 June 2017 Pages: 1287 - 1295

   

6. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden

   • Irene Bertozzi
   • Giulia Bogoni
   • Maria Luigia Randi

   Original Article 06 June 2017 Pages: 1297 - 1302

   

7. Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios

   • Giuseppe Saglio
   • Philipp le Coutre
   • Neil P. Shah

   Original Article Open access 22 May 2017 Pages: 1303 - 1313

   

8. Rethinking the usefulness of bone marrow biopsy on treatment decision in CLL patients at diagnosis

   • Rafet Eren
   • Mehmet Hilmi Doğu
   • Elif Suyanı

   Original Article 24 April 2017 Pages: 1315 - 1321

   

9. Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO)

   • A. García-Noblejas
   • J. Cannata-Ortiz
   • R. Arranz

   Original Article 24 May 2017 Pages: 1323 - 1330

   

10. Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution

    • Yuhua Huang
    • Huilan Rao
    • Yujing Zhang

    Original Article Open access 27 May 2017 Pages: 1331 - 1342

    

11. Assessment of the circulating cell-free DNA marker association with diagnosis and prognostic prediction in patients with lymphoma: a single-center experience

    • Mao Li
    • Yongqian Jia
    • Caigang Xu

    Original Article Open access 16 June 2017 Pages: 1343 - 1351

    

12. Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia

    • Yanmin Zhao
    • Jiasheng Wang
    • He Huang

    Original Article 17 June 2017 Pages: 1353 - 1360

    

13. Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation

    • Michael Heuser
    • Razif Gabdoulline
    • Felicitas Thol

    Original Article 13 June 2017 Pages: 1361 - 1372

    

14. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease

    • Volker Wiebking
    • Sebastian Hütker
    • Michael H. Albert

    Original Article 01 June 2017 Pages: 1373 - 1377

    

15. Impact of non-transferrin-bound iron (NTBI) in comparison to serum ferritin on outcome after allogeneic stem cell transplantation (ASCT)

    • Annekathrin Hilken
    • Claudia Langebrake
    • Nicolaus Kröger

    Original Article 06 June 2017 Pages: 1379 - 1388

    

16. Disease-specific hematopoietic stem cell transplantation in children with inherited bone marrow failure syndromes

    • Qian Li
    • Changying Luo
    • Jing Chen

    Original Article 16 June 2017 Pages: 1389 - 1397

    

17. Co-mutated CALR and MPL driver genes in a patient with myeloproliferative neoplasm

    • Mónica Bernal
    • Pilar Jiménez
    • Manuel Jurado

    Letter to the Editor 17 May 2017 Pages: 1399 - 1401

    

18. Variant of classical high grade PTLD: post-transplant EBV-negative T cell lymphoblastic leukaemia after solid organ transplantation

    • Kristin Teiken
    • Hans Kreipe
    • Kais Hussein

    Letter to the Editor 14 June 2017 Pages: 1403 - 1405

    

19. Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement

    • Chen Tian
    • Hongliang Yang
    • Yizhuo Zhang

    Letter to the Editor 02 June 2017 Pages: 1407 - 1410

    

20. Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation

    • Satoko Oka
    • Kazuo Ono
    • Masaharu Nohgawa

    Letter to the editor Open access 02 June 2017 Pages: 1411 - 1413

    

21. Sweet syndrome secondary to myelodysplastic syndrome mimicking necrotizing fasciitis

    • Kai Shen
    • Bing Xiang
    • Ting Liu

    Letter to the editor 07 June 2017 Pages: 1415 - 1416

    

22. Co-occurrence of type I CALR and two MPL mutations in patient with primary myelofibrosis

    • Hammad Tashkandi
    • Erika M. Moore
    • Navid Sadri

    Letter to the Editor 13 May 2017 Pages: 1417 - 1418

    

23. Erratum to: Good adherence to imatinib therapy among patients with chronic myeloid leukemia—a single-center observational study

    • Sofia Jönsson
    • Bob Olsson
    • Hans Wadenvik

    Erratum 09 June 2017 Pages: 1419 - 1419